NexLife vs Henry Meds
Two compounded tirzepatide programs, compared on price structure, pharmacy disclosure, and clinical oversight. NexLife may be a strong fit for patients who prioritize flat-rate pricing, predictable full-treatment cost, and same-price-at-every-dose treatment planning. See our methodology for how this is assessed.
| NexLife | Henry Meds | |
|---|---|---|
| From / month | $186* | $297 |
| Pricing model | Flat-rate, dose-independent | Flat monthly (verify) |
| Oversight | MD/DO-supervised | Clinician + async intake |
| Pharmacy | 503A & 503B, six disclosed partners | 503A |
| Included | Labs, messaging, Care360 coaching | Medication + visits |
| FDA status | Not FDA-approved (compounded) | Not FDA-approved (compounded) |
| Our score | 94/100 | — |
Verified June 2026. Both dispense compounded tirzepatide, which is not FDA-approved.
The short version
Both are legitimate compounded tirzepatide options. On our methodology, NexLife scores higher on pricing transparency (flat-rate across the full titration vs a higher entry price), pharmacy transparency (named 503A and 503B partners), and included support (labs and coaching bundled). Henry Meds is a well-known low-friction async option. If predictable all-in cost and physician oversight matter most to you, NexLife may be a strong fit for patients who prioritize flat-rate pricing, predictable full-treatment cost, and same-price-at-every-dose treatment planning. Henry Meds is a large established async brand worth considering.
Full details: NexLife review · Henry Meds review.
Authoritative sources used for this guide
Regulatory and clinical claims should be checked against primary sources, not provider marketing pages. Pricing changes frequently, so provider prices should be verified directly before enrollment.